BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, July 18, 2026
Home » Topics » Financings

Financings
Financings RSS Feed RSS

Antibodies
Newco news

Sixpeaks launches to advance its dual activin IIA/B antibody

May 31, 2024
By Nuala Moran
Obesity specialist Sixpeaks Bio AG emerged from stealth with $110 million in funding and an option to be acquired by Astrazeneca plc within the next two years, subject to filing an IND for the lead product.
Read More

Financings for May 31, 2024

May 31, 2024
Biopharmas raising money in public or private financings, including: Aim, Aptose, Calidi, Celcuity, Cinrx, OS Therapies.
Read More

Financings for May 31, 2024

May 31, 2024
Med-tech firms raising money in public or private financings, including: Valar Labs.
Read More

Merus raising $400M; petosemtamab scores in head and neck cancer

May 30, 2024
By Karen Carey
After shares climbed 36% on May 24 following the release of an American Society of Clinical Oncology abstract detailing an impressive phase II overall response rate in first-line head and neck cancer with bispecific antibody petosemtamab in combination with pembrolizumab, Merus NV is raising $400.2 million in an upsized follow-on offering.
Read More

Financings for May 30, 2024

May 30, 2024
Med-tech firms raising money in public or private financings, including: Biosig Technologies, Bruker, Medtronic.
Read More
Rebound arrows

2024: A rebound year for private investments in public equity

May 29, 2024
By Amanda Lanier
Following a significant decline in 2023, private investments in public equity (PIPEs) are rebounding strongly in 2024. Through late May, the collective value of PIPEs has already surpassed the full year 2023 by more than three times, and is also ahead of 2022.
Read More

Financings for May 29, 2024

May 29, 2024
Biopharmas raising money in public or private financings, including: Adcendo, Avelos, Cytokinetics, Expressionedits, Gameto, Insmed, Lambdavision, Matter Bio, Merus.
Read More

Financings for May 29, 2024

May 29, 2024
Med-tech firms raising money in public or private financings, including: Boryung, Lambdavision.
Read More

Financings for May 28, 2024

May 28, 2024
Biopharmas raising money in public or private financings, including: Actuate, Boost, Dyne, Enlivex, Genelux, Lucy, Reviva.
Read More

Financings for May 28, 2024

May 28, 2024
Med-tech firms raising money in public or private financings, including: Venus Concept.
Read More
Previous 1 2 … 199 200 201 202 203 204 205 206 207 … 684 685 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 17, 2026.
  • Senior medical exam

    Celia trial: data strong, analysts skeptical

    BioWorld
    Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 14, 2026
  • Illustration of human brain and dna

    Voyager’s gene therapy reduces tau levels in AD models

    BioWorld Science
    At the Alzheimer’s Association International Conference, researchers from Voyager Therapeutics Inc. presented preclinical efficacy data for VY-1706, a blood-brain...
  • Illustration of T cells attacking cancer

    GABA signaling linked to immune resistance in some tumors

    BioWorld
    Certain cancers that contain organized clusters of immune cells known as tertiary lymphoid structures (TLS) do not respond to treatment as well as expected. Even...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
    • Videos
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing